EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions

Sumsum P Sunny iD, Ravindra D R, Aditi Hariharan, Nirza Mukhia, Shubha Gurudath, Keerthi G, Subhashini Raghavan, Trupti Kolur, Vivek Shetty, Vidya Bushan R, Avadhesha Surolia, Satyajit T und 7 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0291972 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, 2023. Verfasst von Sumsum P Sunny und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology, Mazumdar Shaw Medical Center, Bangalore, India. Hauptthemen laut MEDLINE: Biological Assay, Hyaluronan Receptors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Wellcome Trust DBT India Alliance, GCE-India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high prevalence of oral potentially-malignant disorders exhibits diverse severity and risk of malignant transformation, which mandates a Point-of-Care diagnostic tool. Low patient compliance for biopsies underscores the need for minimally-invasive diagnosis. Oral cytology, an apt method, is not clinically applicable due to a lack of definitive diagnostic criteria and subjective interpretation. The primary objective of this study was to identify and evaluate the efficacy of biomarkers for cytology-based delineation of high-risk oral lesions. A comprehensive systematic review and meta-analysis of biomarkers recognized a panel of markers (n: 10) delineating dysplastic oral lesions. In this observational cross sectional study, immunohistochemical validation (n: 131) identified a four-marker panel, CD44, Cyclin D1, SNA-1, and MAA, with the best sensitivity (>75%; AUC>0.75) in delineating benign, hyperplasia, and mild-dysplasia (Low Risk Lesions; LRL) from moderate-severe dysplasia (High Grade Dysplasia: HGD) along with cancer. Independent validation by cytology (n: 133) showed that expression of SNA-1 and CD44 significantly delineate HGD and cancer with high sensitivity (>83%). Multiplex validation in another cohort (n: 138), integrated with a machine learning model incorporating clinical parameters, further improved the sensitivity and specificity (>88%). Additionally, image automation with SNA-1 profiled data set also provided a high sensitivity (sensitivity: 86%). In the present study, cytology with a two-marker panel, detecting aberrant glycosylation and a glycoprotein, provided efficient risk stratification of oral lesions. Our study indicated that use of a two-biomarker panel (CD44/SNA-1) integrated with clinical parameters or SNA-1 with automated image analysis (Sensitivity >85%) or multiplexed two-marker panel analysis (Sensitivity: >90%) provided efficient risk stratification of oral lesions, indicating the significance of biomarker-integrated cytopathology in the development of a Point-of-care assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological AssayHyaluronan ReceptorsHumansHyperplasiaAutomationBiopsyGlycosylationObservational Studies as Topic

Substanzen

CD44 protein, humanHyaluronan Receptors

Autor:innen und Institutionen

  • Department of Head and Neck Oncology, Mazumdar Shaw Medical Center, Bangalore, India.
  • Integrated Head and Neck Oncology Program (DSRG-5), Mazumdar Shaw Medical Foundation, Bangalore, India.
  • Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Department of Oral Medicine and Radiology, KLE Society's Institute of Dental Sciences, Bangalore, India.
  • Department of Molecular Biophysics, Indian Institute of Science, Bangalore, India.
  • Department of Oral and Maxillofacial Pathology, KLE Society's Institute of Dental Sciences, Bangalore, India.

ORCID-Profile: Sumsum P Sunny, Pavithra Chandrashekhar, Praveen Birur N, Amritha Suresh

Förderung

  • The Wellcome Trust DBT India Alliance
  • GCE-India

Zitieren

APA

Sunny, S. P., D R, R., Hariharan, A., Mukhia, N., Gurudath, S., G, K., Raghavan, S., Kolur, T., Shetty, V., R, V. B., Surolia, A., T, S., Chandrashekhar, P., R, N., Pandya, H. J., Pillai, V., N, P. B., Kuriakose, M. A., & Suresh, A. (2023). CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions. PLOS ONE. https://doi.org/10.1371/journal.pone.0291972

Vancouver

Sunny SP, D R R, Hariharan A, Mukhia N, Gurudath S, G K, et al. CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions. PLOS ONE. 2023. doi:10.1371/journal.pone.0291972

BibTeX
@article{Sunny2023,
  author = {Sunny, Sumsum P and D R, Ravindra and Hariharan, Aditi and Mukhia, Nirza and Gurudath, Shubha and G, Keerthi and Raghavan, Subhashini and Kolur, Trupti and Shetty, Vivek and R, Vidya Bushan and Surolia, Avadhesha and T, Satyajit and Chandrashekhar, Pavithra and R, Nisheena and Pandya, Hardik J and Pillai, Vijay and N, Praveen Birur and Kuriakose, Moni A and Suresh, Amritha},
  title = {CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0291972}
}
Kostenlos starten →